Craft

Nightstar Therapeutics

Nightstar Therapeutics Summary

Company Summary

Overview
Nightstar Therapeutics (formerly known as NightstaRx) is a clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. The Company’s lead product candidate includes NSR-REP1 that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia. It is also developing NSR-RPGR that is in Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, which is in preclinical development for the treatment of Best vitelliform macular dystrophy.
Type
Subsidiary
Status
Closed
Founded
2013
HQ
London, GB | view all locations
Website
https://www.nightstartx.com/
Cybersecurity rating
Sectors

Key People

  • David Fellows

    David Fellows, Chief Executive Officer and Board Member

    • Tuyen Ong

      Tuyen Ong, Chief Development Officer

      • Gregory Robinson

        Gregory Robinson, Chief Scientific Officer

        • Senthil Sundaram

          Senthil Sundaram, CFO

          LocationsView all

          2 locations detected

          • London, England HQ

            United Kingdom

            215 Euston Rd

          • Lexington, MA

            United States

            81 Hartwell Ave #100

          Nightstar Therapeutics Financials

          Summary Financials

          Net income (Q1, 2019)
          ($16.4M)
          Cash (Q1, 2019)
          $94.5M

          Footer menu